Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres

UMMS Affiliation

Department of Biochemistry and Molecular Pharmacology

Publication Date


Document Type



Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Adhesion; Cell Culture Techniques; Cell Death; Cell Division; Cell Line, Tumor; DNA Primers; DNA, Complementary; Dacarbazine; Exons; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Recurrence, Local; Prognosis; Transplantation, Heterologous; Treatment Outcome


Biochemistry, Biophysics, and Structural Biology | Cancer Biology | Pharmacology, Toxicology and Environmental Health


Glioblastoma patients have a poor prognosis, even after surgery, radiotherapy, and chemotherapy with temozolomide or 1,3-bis(2-chloroethy)-1-nitrosourea. We developed an in vitro recovery model using neurosphere cultures to analyze the efficacy of chemotherapy treatments, and tested whether glioblastoma neurosphere-initiating cells are resistant. Concentrations of chemotherapy drugs that inhibit neurosphere formation are similar to clinically relevant doses. Some lines underwent a transient cell cycle arrest and a robust recovery of neurosphere formation. These results indicate that glioblastoma neurospheres can regrow after treatment with chemotherapy drugs. This neurosphere recovery assay will facilitate studies of chemo-resistant subpopulations and methods to enhance glioblastoma therapy.


Cancer Lett. 2010 Oct 28;296(2):168-77.

Journal/Book/Conference Title

Cancer Letters

Related Resources

Link to article in PubMed

PubMed ID